This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    04535609
Previous Study | Return to List | Next Study

An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients (STRIDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04535609
Recruitment Status : Completed
First Posted : September 2, 2020
Results First Posted : April 3, 2024
Last Update Posted : April 3, 2024
Sponsor:
Information provided by (Responsible Party):
Reneo Pharma Ltd

Brief Summary:
This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with PMM.

Condition or disease Intervention/treatment Phase
Primary Mitochondrial Myopathy Drug: Mavodelpar Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 213 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Actual Study Start Date : May 21, 2021
Actual Primary Completion Date : September 12, 2023
Actual Study Completion Date : October 5, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Muscle Disorders

Arm Intervention/treatment
Experimental: Mavodelpar
Once daily
Drug: Mavodelpar
Once daily
Other Name: REN001

Placebo Comparator: Matched placebo
Once daily
Drug: Placebo
Once daily




Primary Outcome Measures :
  1. Change in Distance Walked During a 12 Minute Walk Test [ Time Frame: Baseline to Week 24 ]
    Distance walked in meters


Secondary Outcome Measures :
  1. Change in PROMIS Short Form - Fatigue 13a (FACIT-fatigue) Scores [ Time Frame: Baseline to Week 24 ]
    The PROMIS is a 13-item questionnaire to describe fatigue and its impact upon daily activities and function. Each item is scored between 1=Not At All and 5=Very Much



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects age 18 years or older with PMM as defined by the International Workshop: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adult (Mancuso et al 2017).
  2. A confirmed PMM diagnosis due to known pathogenic gene mutation or deletion of the mitochondrial genome. The Sponsor may authorize local genetic testing at Screening, if required, but results must be available prior to randomization of the subject.
  3. Documented PMM primarily characterized by exercise intolerance or active muscle pain.
  4. Subjects must be ambulatory and able to perform the walking tests independently (walking aids are allowed).
  5. Have no changes to any therapeutic exercise regimen within 30 days prior to Day 1 and be willing to remain on the same therapeutic exercise regimen for the duration of the study.
  6. Females should be either of non-child-bearing potential or must agree to use highly effective methods of contraception from Screening through to 30 days after last dose in the study. Males with partners who are WOCBP must also use contraception.
  7. Concomitant medications (including supplements) must be stable for at least 1 month prior to enrolment and throughout participation in the study.
  8. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion:

  1. Participation in a prior REN001 (previously known as HPP-593) study.
  2. Currently taking or anticipated to need a PPAR agonist during the study.
  3. Subjects with bone deformities or motor abnormalities other than related to the mitochondrial myopathy that may interfere with the outcome measures.
  4. Clinically significant kidney disease or impairment calculated as eGFR Grade 2 or above <60ml/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation at Screening.
  5. Clinically significant liver disease or impairment of AST or ALT Grade 2 or above (>2.5 x ULN), or Total bilirubin > 1.6 x ULN or >ULN with other signs and symptoms of hepatotoxicity at Screening.
  6. Subjects with uncontrolled diabetes and/or a Screening HbA1c of ≥11%.
  7. Evidence of significant concomitant clinical disease that may need a change in management during the study or could interfere with the conduct or safety of this study. (Stable well-controlled chronic conditions such hypercholesterolemia, gastroesophageal reflux, or depression under control with medication (other than tricyclic antidepressants), are acceptable provided the symptoms and medications would not be predicted to compromise safety or interfere with the tests and interpretations of this study.)
  8. Subjects with a history of cancer. A history of in situ basal cell carcinoma in the skin is allowed.
  9. Clinically significant cardiac disease and/or clinically significant ECG abnormalities such as 2nd degree heart block, symptomatic tachyarrhythmia or unstable arrythmia (right bundle branch block, left fascicular block and long PR interval are not excluded) that in the opinion of the Investigator should exclude the subject from completing exercise tests.
  10. Evidence of hospitalization for rhabdomyolysis within the year prior to enrolment.
  11. Pregnant or nursing females.
  12. History of sensitivity to PPAR agonists.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04535609


Locations
Show Show 41 study locations
Sponsors and Collaborators
Reneo Pharma Ltd
Investigators
Layout table for investigator information
Principal Investigator: Amel Karaa, MD Massachusetts General Hospital (MGH)
  Study Documents (Full-Text)

Documents provided by Reneo Pharma Ltd:
Study Protocol  [PDF] June 24, 2022
Statistical Analysis Plan  [PDF] November 16, 2023

Layout table for additonal information
Responsible Party: Reneo Pharma Ltd
ClinicalTrials.gov Identifier: NCT04535609    
Other Study ID Numbers: REN001-201
First Posted: September 2, 2020    Key Record Dates
Results First Posted: April 3, 2024
Last Update Posted: April 3, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Diseases
Mitochondrial Myopathies
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Mitochondrial Diseases
Metabolic Diseases